Compare BridgeBio Pharma Inc (BBIO) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Skyworks Solutions Inc — how do they compare? BridgeBio Pharma Inc trades at $83.54 (market cap $16.36B), while Skyworks Solutions Inc trades at $67.82 (market cap $10.28B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Skyworks Solutions Inc pays a 4.13% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SWKS | |
|---|---|---|
Market Cap | $16.36B | $10.28B |
Sector | Health | Technology |
52-Week High | $90.17 | $83.40 |
52-Week Low | $47.29 | $52.50 |
Enterprise Value | $18.14B | $10.16B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
Skyworks Solutions (SWKS) trades at $68.79, down 2.59% on the day, showing mixed technical signals with bullish moving averages but neutral oscillators. The company delivered three consecutive quarterly earnings beats, with Q3 2026 EPS of $1.08 exceeding expectations by $0.05. Revenue trends show contraction from $5.5B in 2022 to $4.1B in 2025, while profit margins declined from 23.24% to 11.67% over the same period. The pending Qorvo combination represents a significant strategic development, with regulatory approvals progressing and leadership teams announced.
The stock faces headwinds from revenue contraction and margin pressure, but strong institutional buying and analyst optimism (58% buy ratings) provide support. Key risks include integration challenges with Qorvo, ongoing margin compression, and mobile market concentration. Upside potential exists if the combination delivers synergies and AI data center growth accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
